Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
06 09 2019
Historique:
received: 13 06 2019
accepted: 20 08 2019
entrez: 8 9 2019
pubmed: 8 9 2019
medline: 23 10 2020
Statut: epublish

Résumé

An early bottleneck in the rapid isolation of new antibody fragment binders using in vitro library approaches is the inertia encountered in acquiring and preparing soluble antigen fragments. In this report, we describe a simple, yet powerful strategy that exploits the properties of the SpyCatcher/SpyTag (SpyC/SpyT) covalent interaction to improve substantially the speed and efficiency in obtaining functional antibody clones of interest. We demonstrate that SpyC has broad utility as a protein-fusion tag partner in a eukaryotic expression/secretion context, retaining its functionality and permitting the direct, selective capture and immobilization of soluble antigen fusions using solid phase media coated with a synthetic modified SpyT peptide reagent. In addition, we show that the expressed SpyC-antigen format is highly compatible with downstream antibody phage display selection and screening procedures, requiring minimal post-expression handling with no sample modifications. To illustrate the potential of the approach, we have isolated several fully human germline scFvs that selectively recognize therapeutically relevant native cell surface tumor antigens in various in vitro cell-based assay contexts.

Identifiants

pubmed: 31492910
doi: 10.1038/s41598-019-49233-7
pii: 10.1038/s41598-019-49233-7
pmc: PMC6731262
doi:

Substances chimiques

Antibodies 0
Antigens 0
Epitopes 0
Single-Chain Antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12815

Références

Mol Ther. 2012 Mar;20(3):633-43
pubmed: 22127019
Methods Mol Biol. 2017;1558:41-55
pubmed: 28150232
J Vis Exp. 2015 Jan 17;(95):51492
pubmed: 25651360
Chem Commun (Camb). 2018 Jan 31;54(10):1189-1192
pubmed: 29334085
Anal Biochem. 1999 Jan 1;266(1):9-15
pubmed: 9887208
Cancer Lett. 2007 Oct 8;255(2):263-74
pubmed: 17560019
Curr Opin Chem Biol. 2015 Jun;26:16-24
pubmed: 25626152
Anticancer Agents Med Chem. 2013 Feb;13(2):276-80
pubmed: 22721387
Protein Expr Purif. 2004 Sep;37(1):243-52
pubmed: 15294305
Anal Biochem. 1998 Sep 10;262(2):122-8
pubmed: 9750126
Scand J Immunol. 2002 Nov;56(5):436-42
pubmed: 12410792
J Biol Chem. 1996 Jun 28;271(26):15353-7
pubmed: 8663064
J Immunol Methods. 2006 Dec 20;317(1-2):1-11
pubmed: 17109880
Chem Commun (Camb). 2016 Nov 29;52(97):14051-14054
pubmed: 27854365
Protein Expr Purif. 2001 Apr;21(3):417-23
pubmed: 11281716
Blood. 2000 Mar 15;95(6):2098-103
pubmed: 10706880
Sci Rep. 2016 Jan 19;6:19234
pubmed: 26781591
J Clin Oncol. 2016 Dec;34(34):4171-4179
pubmed: 27863199
Chembiochem. 2017 Nov 16;18(22):2217-2221
pubmed: 28891272
Nucleic Acids Res. 2002 Jan 15;30(2):E9
pubmed: 11788735
Protein Expr Purif. 2007 Apr;52(2):320-8
pubmed: 17084093
Clin Cancer Res. 2008 May 1;14(9):2647-55
pubmed: 18451228
J Mol Biol. 2014 Jan 23;426(2):309-17
pubmed: 24161952
Protein Eng. 1998 Jun;11(6):495-500
pubmed: 9725629
Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16268-73
pubmed: 15534202
Biotechniques. 2005 May;38(5):696, 698
pubmed: 15945366
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E690-7
pubmed: 22366317
Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):E1176-81
pubmed: 24639550
J Immunol. 1995 Aug 1;155(3):1544-55
pubmed: 7636216
Biomacromolecules. 2016 Sep 12;17(9):2812-9
pubmed: 27477779
PLoS One. 2016 Mar 30;11(3):e0152386
pubmed: 27029048
Methods Mol Biol. 2015;1266:171-84
pubmed: 25560075
Anal Biochem. 2004 Apr 15;327(2):278-83
pubmed: 15051546
Mol Biosyst. 2016 Jul 19;12(8):2342-58
pubmed: 27306919
Biomol Eng. 2007 Sep;24(3):283-91
pubmed: 17379573
Anal Biochem. 1993 Apr;210(1):179-87
pubmed: 8489015
Cancer Immunol Immunother. 2017 Mar;66(3):367-378
pubmed: 27933426
J Biol Chem. 2003 Feb 14;278(7):4500-9
pubmed: 12407102
J Biomol Screen. 2009 Mar;14(3):282-93
pubmed: 19224869
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
EMBO J. 2013 May 15;32(10):1478-88
pubmed: 23584533
Curr Protoc Protein Sci. 2001 May;Chapter 3:Unit 3.6
pubmed: 18429171
FASEB J. 2006 Aug;20(10):1599-610
pubmed: 16873883

Auteurs

Julie K Fierle (JK)

Department of Oncology, Ludwig Institute for Cancer Research Lausanne, University of Lausanne, Lausanne, Switzerland.

Johan Abram-Saliba (J)

Department of Oncology, Ludwig Institute for Cancer Research Lausanne, University of Lausanne, Lausanne, Switzerland.

Matteo Brioschi (M)

Department of Oncology, Ludwig Institute for Cancer Research Lausanne, University of Lausanne, Lausanne, Switzerland.

Mariastella deTiani (M)

Department of Oncology, Ludwig Institute for Cancer Research Lausanne, University of Lausanne, Lausanne, Switzerland.

George Coukos (G)

Department of Oncology, Ludwig Institute for Cancer Research Lausanne, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Steven M Dunn (SM)

Department of Oncology, Ludwig Institute for Cancer Research Lausanne, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. steven.dunn@chuv.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH